Ventura County Jail Recent Arrests, Charles Keating Iv Wife, Saint James Methodist Church, Articles N

Press release content from Business Wire. At the same time, the Group aims to increase its earning power and create value through innovation and growth. 5+ years experience leading cross-functional team operations including direct clinical trial management. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, acunningham@kleinhersh.comour staffing partner atKlein Hersh. Scott Chappel - Executive Partner at MPM Capital | The Org life. We also use cookies and similar technologies for purposes of marketing and advertising. Healthy Families, Leaps by The investment portfolio includes more than 50 companies. The financing will be used to advance NextPoint . This website is intended to provide information to an international audience outside the USA and UK. Tuesday's. NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. Copyright and Legal Notice. solutions Inside the structure of OpenAI's looming new investment from Microsoft Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. Safety, Science in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. Sustainability 50 NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). The Bayer brand stands for trust, reliability and quality throughout the world. Compliance Policy, Bayer Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. for NextPoint Therapeutics Raises $80 Million in Series B | citybiz We use technical and organizational security measures designed to secure and protect Personal Data. Kong, China, Ireland, The securities mentioned herein have not been, and will not be, registered under the Securities Act Phone: +49 30 468 1111, Alfred-Nobel-Str. available on the website of the Luxembourg Stock Exchange (www.bourse.lu). As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? ProBioGen Executes a Master Service Agreement with NextPoint Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. Rica, Czech These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. Your computer and mobile devices when you access our Site. Bayers leadership in agriculture provides tailored solutions For more information, go to leaps.bayer.com. Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise FAQs, Digital Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. 13353 Berlin For more information. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. for Prescription Medicine in Europe, Counterfeits in As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. Science, Business circumstances, constitute a public offering or an invitation to the public in connection with any Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. 40789 Monheim am Rhein & Stories, Working Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. Bayer and the opportunities available. Secret of the Bridge, Rice Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. These electronic materials are thus extremely vulnerable to unauthorized distribution and copyright infringement. NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. Plentiful sunshine. An investment decision regarding the securities referred to herein should only Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. Kaiser-Wilhelm-Allee 1 Reports, Bayer AG Development Policy, Corporate Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. Nutrition Lanka, Taiwan, ////// Science for a better Furthermore, where permissible, we may charge for this service. We'd love to talk to you. OriCell Therapeutics-Committed to developing novel immunotherapies Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Stock Market | FinancialContent Business Page CAMBRIDGE, Mass. The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. Up and down the ladder: The latest comings and goings on Breakpoint Therapeutics - Evotec We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical You can use our locations menu to find Bayer country websites and The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. Locations, Your Settings. Natural Scientists, Global requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. | Learn more about Anne Koehler, PhD's . The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Information, Analyst There will be no 616 followers 500+ connections. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. be made at any time under the following exemptions from the Prospectus Directive, if they have been Distances, Work Tool, Innovation Postings, Latest For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Consensus, Return 14 new chief medical officers in February We will never disclose your PII to third parties for direct marketing purposes without your authorization. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are farmers to plant, grow and protect their harvests using less and may not be offered or sold in the United States, except pursuant to an exemption from, or in a The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. Wei Y, Ren X, Galbo PM Jr, et al. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. Contact Us - Nextpoint COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. States and the tender offer cannot be accepted by any such use, means, instrumentality or facility HR Trainee Program, International Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. Rights Policy, Responsible Bayer is an innovation company with a more than 150-year history. Bayer Global We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. We do not knowingly collect information from minors under the age of 13 years without parental consent. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Authority, Saudi Proc Natl Acad Sci U S A. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. R&D expenses before special items amounted to 5.3 billion euros. Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is us, Talent Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or A spokesperson for Boston-based NextPoint declined . It was the company's first announced funding. Bayer. offered or sold +49 2173 380. Slavery Act Statement, Position Further, it does not constitute a Stories, Annual the securities prospectus. Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Bayer, Research and Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The investment portfolio includes more than 50 companies. at the Forefront, Consumer Health He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. Menu, Our 2021 Jul 9;6(61):9792. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. herein The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Looking for a job in an innovative company? Bar on Crop Protection Safety Standards, UN About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Sustainable Beef Production, Responsible Business Kaiser-Wilhelm-Allee 1 INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. NextPoint Therapeutics Raises $80M in Series B Financing Protection, Environmental local requirements that prohibit or restrict them from doing so. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Trends, Rise Potential, Leading The United States data protection and other laws might not be as comprehensive as those in your country. Bayer Athletes, Disabled Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). & Teamwork, Better Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. In other jurisdictions, only certain categories of person may be allowed to view such For more information, go to www.bayer.com. Dialogue, UN Global for NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. Germany to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). Sci Immunol. Education, Health, And here is our regular feature in which we highlight a different person each week. Our Privacy Notice does not apply to Third-Party Sites. Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. of Biodiversity, Modern NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. & Rewards, Values language options. 1 Wei Y, Ren X, Galbo PM Jr, et al. Arabia, South of in the United States absent registration or an applicable exemption from the registration Bayer Global Leaps by Bayer and Sanofi Ventures co-led the round and were joined . in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Further, it does Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. & Proposals for Election, Stockholder Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. Drs. The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. We provide these links merely for your convenience. 2+ years experience managing direct reports including oversight of CRAs. language options. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. 40789 Monheim am Rhein Council, Stakeholder Results, AGM We do not accept any responsibility or liability for these policies and procedures. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. NextPoint Therapeutics Announces $80 Million Series B Financing co-led Experience preparing for and managing FDA and other regulatory authority audits/inspections. 51373 Leverkusen I agree to be bound by its terms. our employees, International Please note that Google has its own privacy policies which are independent from ours. +49 30 468 1111, Alfred-Nobel-Str. The Week's 10 Biggest Funding Rounds: Monogram And ShiftKey Land Huge A browser sends cookies to a server when the browser makes a connection to the server (for example, when requesting a web page from the same domain that created the cookie). Zealand, Palestinian 6. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Monsanto, How to not subject to any local requirements that prohibit or restrict them from doing so. Global, Data Privacy Information For Specific Processing Activities, Stem cells - The new age of medical research, Moving Non-Communicable Diseases Care Forward, Inspiring Creativity and Improving Health, EU Verification Logo against Counterfeit Drugs, New Safety Features for Prescription Medicine in Europe, Reducing Crop Protections Environmental Impact, Environmental Impact Reduction Reporting Results, Sustainable Agriculture in practice: Bayer Forward Farms, Conserving Natural Resources in Agriculture, Position on Deforestation and Forest Degradation, Raising the Bar on Crop Protection Safety Standards, Transfers of Values to Healthcare Professionals, Collaboration with Healthcare Professionals, Sustainability & Socially Responsible Investing, Duties and Activities of the Board of Management, International Trainee Program for Financial Management, International Future Leadership Program - Engineers, Global Supply Chain Management Trainee Program, International Procurement Management Trainee Program, International Future Leadership Program - Pharmaceuticals and Consumer Health Product Supply, Advanced